Alice W. Flaherty

Alice W. Flaherty

Auto-generated profile, based on publicly available information

Alice W. Flaherty

Departments of Neurology and Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
MNMartin Niethammer
Martin Niethammer
CTChris C. Tang
Chris C. Tang
PLPeter A. LeWitt
Peter A. LeWitt
ARAli R. Rezai
Ali R. Rezai
MLMaureen A. Leehey
Maureen A. Leehey
AFAndrew Feigin
Andrew Feigin
BACKGROUND. We report the 12-month clinical and imaging data on the effects of bilateral delivery of the glutamic acid decarboxylase gene into the subthalamic nuclei (STN) of advanced Parkinson’s disease (PD) patients. METHODS. 45 PD patients were enrolled in a 6-month double-blind randomized trial of bilateral AAV2- GAD delivery into the STN compared with sham surgery and were followed for 12 months in open-label fashion. Subjects were assessed with clinical outcome measures and 18 F-fluorodeoxyglucose (FDG) PET imaging. RESULTS. Improvements under the blind in Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores in the AAV2- GAD group compared with the sham group continued at 12 months [time effect: F (4,138) = 11.55, P < 0.001; group effect: F (1,35) = 5.45, P < 0.03; repeated-measures ANOVA (RMANOVA)]. Daily duration of levodopa-induced dyskinesias significantly declined at 12 months in the AAV2- GAD group ( P = 0.03; post-hoc Bonferroni test), while the sham group was unchanged. Analysis of all FDG PET images over 12 months revealed significant metabolic declines ( P < 0.001; statistical parametric mapping RMANOVA) in the thalamus, striatum, and prefrontal, anterior cingulate, and orbitofrontal cortices in the AAV2- GAD group compared with the sham group. Across all time points, changes in regional metabolism differed for the two groups in all areas, with significant declines only in the AAV2- GAD group ( P < 0.005; post-hoc Bonferroni tests). Furthermore, baseline metabolism in the prefrontal cortex (PFC) correlated with changes in motor UPDRS scores; the higher the baseline PFC metabolism, the better the clinical outcome. CONCLUSION. These findings show that clinical benefits after gene therapy with STN AAV2- GAD in PD patients persist at 12 months. TRIAL REGISTRATION. ClinicalTrials.gov NCT00643890. FUNDING. Neurologix Inc.

1 December 2020 in Neurology Clinical Practice
Verified
Journal Article
Open access
PDF file
DPDavid L. Perez
David L. Perez
AHAnn Hunt
Ann Hunt
NSNutan Sharma
Nutan Sharma
AFAlice Flaherty
Alice Flaherty
DCDavid Caplan
David Caplan
JSJeremy D. Schmahmann
Jeremy D. Schmahmann
Functional neurologic disorder (FND), although neglected for much of the 20th century, is among the most common conditions encountered by neurologists across clinical settings. High prevalence rates and limited provider expertise in FND have created a considerable need to develop educational initiatives and practical suggestions to guide neurologists in training working with this population. To help avoid diagnostic errors, trainees should keep in mind that (1) marginally positive functional examination signs have low specificity; (2) FND can coexist with other neurologic comorbidities; and (3) bizarre, not previously encountered, neurologic presentations should not be mistakenly diagnosed as FND. Furthermore, trainees should be encouraged to longitudinally follow in their clinics a subset of patients with FND to develop the interview, diagnostic, and neuropsychiatric skills needed to effectively care for this population. As the landscape of neurologic care evolves, neurologists with expertise in FND should advise on shaping elements of the educational curriculum for neurology residents.

10 September 2018 in eLife
Verified
Journal Article
Open access
SPShaun R Patel
Shaun R Patel
THTodd M Herrington
Todd M Herrington
SSSameer A Sheth
Sameer A Sheth
MMMatthew Mian
Matthew Mian
SBSarah K Bick
Sarah K Bick
EEEmad N Eskandar
Emad N Eskandar
The subthalamic nucleus (STN) is a small almond-shaped subcortical structure classically known for its role in motor inhibition through the indirect pathway within the basal ganglia. Little is known about the role of the STN in mediating cognitive functions in humans. Here, we explore the role of the STN in human subjects making decisions under conditions of uncertainty using single-neuron recordings and intermittent deep brain stimulation (DBS) during a financial decision-making task. Intraoperative single-neuronal data from the STN reveals that on high-uncertainty trials, spiking activity encodes the upcoming decision within a brief (500 ms) temporal window during the choice period, prior to the manifestation of the choice. Application of intermittent DBS selectively prior to the choice period alters decisions and biases subject behavior towards conservative wagers.

6 July 2022 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
AFAlice Flaherty
Alice Flaherty
DKDouglas Katz
Douglas Katz
ACAnne Chosak
Anne Chosak
MHMichael E. Henry
Michael E. Henry
NTNhi-Ha Trinh
Nhi-Ha Trinh
JCJonah N. Cohen
Jonah N. Cohen
Six clinicians from different disciplines discuss the case of a woman who, after 20 years, finally achieved symptom relief when her primary complaint of “labored thinking” was targeted specifically.

1 January 2008
Verified
Book Chapter
Closed access
RARobert S. Abernethy
Robert S. Abernethy
AAAnnah N. Abrams
Annah N. Abrams
AAAnne Alonso
Anne Alonso
MAMenekse Alpay
Menekse Alpay
JAJonathan E. Alpert
Jonathan E. Alpert
Albert YeungAlbert Yeung
Albert Yeung